Share on StockTwits

Galectin Therapeutics (NASDAQ:GALT) Director Kevin D. Freeman purchased 1,000 shares of Galectin Therapeutics stock on the open market in a transaction that occurred on Friday, August 15th. The stock was purchased at an average cost of $4.70 per share, for a total transaction of $4,700.00. Following the completion of the acquisition, the director now directly owns 3,917 shares of the company’s stock, valued at approximately $18,410. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Galectin Therapeutics (NASDAQ:GALT) traded down 1.26% on Monday, hitting $4.72. The stock had a trading volume of 164,820 shares. Galectin Therapeutics has a 52-week low of $4.28 and a 52-week high of $19.11. The stock’s 50-day moving average is $10.20 and its 200-day moving average is $12.76. The company’s market cap is $104.0 million.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings data on Thursday, August 7th. The company reported ($0.17) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.21) by $0.04. Analysts expect that Galectin Therapeutics will post $-1.03 EPS for the current fiscal year.

GALT has been the subject of a number of recent research reports. Analysts at Aegis downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 1st. Separately, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Galectin Therapeutics in a research note on Tuesday, July 29th. Finally, analysts at MLV & Co
cut their price target on shares of Galectin Therapeutics from $27.00 to $15.00 in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock.

Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.